High Unmet Medical Need in Brachioradial Pruritus: Results from a Large Patient Survey
Elinor Artsy Navon, MD
Dysphagia and its Relationship to Medication Intake in Parkinson's Disease
Elijahu Berkovich, PhD and Dorit Mimrod, PhD
OLAR®: A Novel Oral Long Acting Release (OLAR®) platform
Menashe Levy
Sleep problems in Parkinson’s Disease: PD patients’ survey on common issues and treatments expectations
Elijahu Berkovich, PhD
CLE-400 for Chronic Neuropathic Itch
Yael Rosen, MD
CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson's disease with the OLAR platform Elijahu Berkovich, PhD
Learn MoreCLE 400 a potent alpha 2 adrenergic receptor agonist for the treatment of chronic itch
Elanite Caspi, PhD
CLE-400 a Potent Analgesic Topical Gel in Acute and Chronic Pain Pig Models.
Elanite Caspi, PhD
CLE-400 a potent alpha 2 adrenergic receptor agonist for the treatment of chronic itch
Johanna Schumann, PhD
CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson’s disease with the OLAR® platform
Elijahu Berkovich, PhD
CLE-400 a novel non-opioid topical treatment for painful diabetic neuropathy
Orna Goren, PhD
Introducing the OLAR platform
Elijahu Berkovich, PhD